Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways

Figure 7

Dual effects of Vericiguat on osteoclast differentiation and bone resorption via a balance between VASP and NF-κB. (a, b) The expression of NF-κB protein in BMMs treated with Vericiguat only (). indicated a comparison with the control group (Vericiguat, 0 nM). (c) (A) The predicted optimal binding manner of Vericiguat at the ATP binding site of IKKβ protein; hydrogen bonds (yellow lines). (B) MOLCAD representation showed the molecular lipophilic potential surface upon the bioactive pose of Vericiguat at the ATP binding site of IKKβ. The blue represented hydrophilic, red represented lipophilic, and gray represented neutral moiety. Hydrogen bonds were displayed as yellow lines. (C) The overlap analysis of Vericiguat and the ligand of IKKβ and the participating amino acid residue (Thr23) were marked. (d) TRAP staining of RANKL-induced BMMs treated with Vericiguat with or without the NF-κB inhibitor ROC-A. (e, f) The expression of NF-κB in RANKL-induced BMMs treated with Vericiguat with or without the NF-κB inhibitor ROC-A. .

(a)

(b)

(c)

(d)

(e)

(f)